INTRODUCTION {#S1}
============

The defining symptom of cancer cachexia is unintentional weight loss because of depletion of skeletal muscle. This wasting cannot be prevented by supplemental nutrition and is often correlated with increased whole-body inflammation and anorexia ([@R6]). Cachexia occurs in at least half of all cancer patients and is associated with advanced disease and palliative care. However, in gastrointestinal malignancies, especially pancreatic ductal adenocarcinoma (PDA), cachexia often presents much earlier, with approximately 70% of PDA patients meeting cachexia criteria at cancer diagnosis ([@R20]; [@R46]).

With a 9% 5-year survival rate and increasing incidence rates, PDA remains a devastating disease ([@R4]). Although resistance to current therapies and the difficultly of diagnosing early-stage malignancy are important contributors to the high mortality rate of PDA patients, the cachexia syndrome also contributes to poor survival in this disease by lowering patient tolerance of chemo- and radiotherapy ([@R5]; [@R7]; [@R31]; [@R45]; [@R49]; [@R67]). Thus, as the search continues to more effectively diagnose and treat PDA, managing cachexia provides an additional strategy to decrease patient morbidity and mortality.

Despite the clear need to prevent and treat cachexia, therapies are currently lacking, as evidenced by two recent phase III clinical trials that failed to achieve their primary endpoints ([@R35]; [@R63]). Although a number of factors likely contributed to the failure of these trials, one limitation may be the animal models currently used to study cancer cachexia. Two commonly used mouse models are xenograft colon-26 (C-26) and Lewis lung carcinoma (LLC) ([@R1]; [@R13]; [@R26]; [@R30]; [@R50]; [@R60]; [@R74]). Although these models have been useful for our laboratory and others in elucidating numerous mechanisms of tissue wasting, they often come under scrutiny for their inability to fully recapitulate the phenotype of human cancers, either by not forming spontaneous tumors or because of their inability to reconstitute a tumor microenvironment. These models are used in a tumor-agnostic manner and are also quite large, typically representing more than 10% of the entire body mass ([@R60]; [@R74]). They are also aggressive and induce cachexia on a timescale of only a few weeks ([@R53]; [@R59], [@R60]).

In this study, we tested for a disparity between mice and humans by comparing global gene expression changes in skeletal muscles from C-26 and LLC-bearing mice compared with biopsies obtained from PDA patients with cachexia. The results revealed little overlap in both the number and classification of genes expressed, emphasizing that, on the molecular level, these models may not be the most appropriate to study human cachexia. In addition to these xenograft models, the classic genetically engineered mouse model (GEMM) of PDA, called the Kras; p53; Cre (KPC) mouse, is gaining attraction in cachexia studies. However, as we reveal, this model also has limitations that question its usefulness to study cachexia. Such findings prompted us to design a mouse model of PDA to better reflect the features of human cancer-induced wasting.

RESULTS {#S2}
=======

The C-26 and LLC Models Do Not Resemble the Muscle Gene Expression Signature of PDA Patients {#S3}
--------------------------------------------------------------------------------------------

To assess the ability of the C-26 and LLC models to reflect PDA-induced cachexia, we compared differences between control and cachectic transcriptional profiles determined by RNA sequencing (RNA-seq) with differences between cachectic pancreatic cancer patients and control patients. In the C-26 model, using a false discovery rate (FDR) of \< 0.05, we identified 3,474 differentially expressed genes (DEGs) between control and cachectic muscles ([Figure 1A](#F1){ref-type="fig"}; [Table S1](#SD2){ref-type="supplementary-material"}), which is consistent with published microarray data ([@R11]; [@R15]; [@R30]). For the LLC model, we identified 788 DEGs ([Figure 1A](#F1){ref-type="fig"}; [Table S1](#SD2){ref-type="supplementary-material"}), again within the range of published data ([@R9]). Although the LLC model demonstrated fewer DEGs than C-26 mice, gene ontology analysis showed that DEGs from both models were generally associated with processes of RNA translation ([Figure S1A](#SD1){ref-type="supplementary-material"}). Interestingly, when similar gene expression profiling was performed with cachectic PDA patients, only 141 DEGs were identified compared with weight-stable patients without cancer ([Figure 1B](#F1){ref-type="fig"}; [Table S1](#SD2){ref-type="supplementary-material"}). Although these DEGs were too few to associate with a biological process by gene ontology, all five cellular components that associated with these DEGs involved the extracellular matrix ([Figure S1B](#SD1){ref-type="supplementary-material"}).

A striking feature of these results was that more than 95% of the DEGs from human muscle were decreased in cachectic patients, which we confirmed by qRT-PCR ([Figure S1C](#SD1){ref-type="supplementary-material"}); this is consistent with previous findings in cachectic patients with upper gastrointestinal (GI) malignancies ([@R22]). This gene expression pattern stands in stark contrast to the overwhelming upregulation of genes seen in the C-26 model (80% upregulated) or the approximately equal proportions of up-regulated and downregulated DEGs observed in LLC tumor-bearing mice.

These results suggested that the gene signatures in muscle from the standard C-26 and LLC models of cancer cachexia are distinct from that of muscle from cachectic pancreatic cancer patients. To test for a discordance specifically in relation to muscle atrophy, we measured the expression of genes coding for components of the ubiquitin proteasome and autophagy systems, which are considered to be causative in cancer-induced muscle wasting ([@R64]). The results showed the typical large increase in expression of the E3 ubiquitin ligases MuRF1 and Atrogin-1 in C-26 and LLC models, whereas no changes in the expression of these genes were seen in muscles from cachectic PDA patients ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). Expression of the autophagy genes Atg5 and Bnip3 was also increased in muscle from C-26 and LLC mice but remained unchanged in cachectic PDA patients ([Figures 1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}). A similar lack of transcriptional changes in these genes in cachectic patients has been reported by other groups ([@R12]; [@R16]). Collectively, we conclude from these data that xenograft C-26 and LLC models are not optimal to recapitulate the muscle wasting phenotype of human cancer-induced cachexia.

KPC Mice Exhibit Variability and Tissue Mass Changes that Do Not Correlate with Pancreatic Cancer Progression {#S4}
-------------------------------------------------------------------------------------------------------------

Next we tested the established KPC GEMM of PDA ([@R27]), which has recently been described as a model of cachexia ([@R48]; [@R51]; [@R54]). KPC mice utilize the *Pdx1* promoter to drive Cre recombinase to express mutant *Kras^G12D^* as well as either a floxed or a lox-stop-lox (LSL) mutant allele of *Trp53,* leading mice to a median survival of approximately 150 days ([Figure S2A](#SD1){ref-type="supplementary-material"}; [@R27]; [@R56]). Consistent with previous reports, we too observed that KPC mice (*Kras*^+/LSL-G12D^, *Trp53*^+/R270H^, *Pdx1^+/Cre^*) that reached endpoint criteria weighed significantly less than their littermate controls ([Figures 2A](#F2){ref-type="fig"} and [S2B](#SD1){ref-type="supplementary-material"}). This reduction in weight correlated with reduced hindlimb muscle (tibialis anterior \[TA\], quadriceps \[QUAD\], and gastrocnemius \[GAST\]) mass and lower white adipose tissue mass ([Figures 2B](#F2){ref-type="fig"}, [S2C](#SD1){ref-type="supplementary-material"}, and [2C](#F2){ref-type="fig"}). However, when correlating body weight and muscle wasting with pancreas pathology, we were surprised to find that KPC mice tended to be smaller than their littermate control mice regardless of the severity of their pancreatic disease ([Figure 2D](#F2){ref-type="fig"}, [2E](#F2){ref-type="fig"}, and [S2D](#SD1){ref-type="supplementary-material"}). In fact, some KPC mice with non-invasive pancreatic lesions (referred to as mPanIN) were among the smallest mice compared with their littermates, whereas other mice with advanced PDA were of similar weight as their littermate controls ([Figure S2E](#SD1){ref-type="supplementary-material"}). Similarly, KPC mice tended to have smaller muscle mass regardless of pancreas pathology ([Figure 2F](#F2){ref-type="fig"}). Consistent with the heterogeneity of the model, an RNA-seq analysis of muscle from KPC mice similar to the one performed for the C-26 and LLC models returned only a single DEG (FDR \< 0.05; [Table S1](#SD2){ref-type="supplementary-material"}). These results are not in keeping with PDA patients, where lower body and peripheral tissue masses are associated with cancer.

Generation of the KPP Mouse {#S5}
---------------------------

Given the limitations we identified in both xenograft models and KPC mice, we turned our efforts to generating another model of cancer-induced wasting. When developing this model, we considered several aspects reflective of human disease. First, we sought to model PDA because this disease has among the highest incidences and severities of cancer cachexia ([@R8]). Next, because PDA develops in adults, we wanted to induce cancer in postnatal mice. Further, we sought to achieve a direct association between the development of PDA and an ensuing cachexia condition. Specifically, because patients with PDA-induced cachexia lose existing muscle and fat, we sought to model true tissue wasting as opposed to a condition of "perceived wasting," where tissues do not gain mass because they fail to develop. Finally, we wanted a model that developed cachexia on a slower timescale than the rapid wasting that occurs in current xenograft models.

To meet these criteria, we started with the same *LSL-Kras*^G12D^ mutant allele found in the KPC mouse but removed the stop cassette with a tamoxifen-inducible Cre recombinase driven by the *Ptfla* promoter, also known as *p48,* which remains active into adulthood in the pancreas ([@R47]). Our model also used two floxed alleles of the tumor suppressor *Pten* that were inactivated at the same time mutant *Kras* was induced ([@R57]; [@R73]). Over 70% of human pancreatic tumors demonstrate reduced Pten protein expression, making *Pten* deletion relevant to pancreatic cancer patients ([@R29]; [@R73]). Together, these mice exhibit the genotype *Kras*^+/*G12D*^,*Ptf1a*^+/*ER-Cre*^, *Pten^f/f^* ([Figure 3A](#F3){ref-type="fig"}), which we named KPP.

We first confirmed that the *Ptf1a^ER-Cre^* promoter is active only in the presence of tamoxifen by breeding *Ptf1a*^+/*ER-Cre*^mice to Rosa26-tdTomato reporter mice ([@R42]). Mice treated with five consecutive injections of tamoxifen expressed Tomato in acinar cells throughout the pancreas, whereas Tomato expression was not present in *Ptf1a*^+/*ER-Cre*^ mice not treated with tamoxifen ([Figure 3B](#F3){ref-type="fig"}). To initiate tumorigenesis, KPP mice were injected with tamoxifen between 24 and 28 days of age. At this age, there was no difference in body mass between control and KPP mice ([Figure S3A](#SD1){ref-type="supplementary-material"}). With 100% penetrance, KPP mice reached endpoint criteria (ascites, weight loss, and lethargy) at a median age of 107 days ([Figure 3C](#F3){ref-type="fig"}). In comparison, all control mice showed no obvious phenotype at this age (genotypes for each control mouse can be found in [Table S4](#SD1){ref-type="supplementary-material"}). At the endpoint, the weights of KPP pancreata were significantly increased compared with littermate controls, consistent with tumor burden ([Figure S3B](#SD1){ref-type="supplementary-material"}). Histological analysis demonstrated well-differentiated to moderately well-differentiated ductal adenocarcinomas composed of anastomosing and branching glands lined by mucinous epithelium accompanied by abundant fibrous stromata. The pancreatic parenchyma was extensively replaced by the neoplasms ([Figure 3D](#F3){ref-type="fig"}; [Figure S3C](#SD1){ref-type="supplementary-material"}). Cystic glands with intraluminal papillary projections were often noted. Expression of cytokeratin 19 (CK19) demonstrated the ductal phenotype of the glandular epithelium, and Alcian blue staining confirmed the presence of mucin. Additional staining for Ki-67 and α-smooth muscle actin revealed epithelial and stromal proliferative activity and the presence of large numbers of stromal myofibroblasts, respectively ([Figure 3D](#F3){ref-type="fig"}; [Figure S3C](#SD1){ref-type="supplementary-material"}; [@R3]).

KPP Mice Exhibit a Cachectic Phenotype {#S6}
--------------------------------------

We next sought to evaluate whether KPP mice suffered from cachexia. KPP mice at their endpoint exhibited decreased body weight compared with their littermate controls ([Figure 4A](#F4){ref-type="fig"}; [Figure S4A](#SD1){ref-type="supplementary-material"}) but, importantly, had similar tibia lengths ([Figure 4B](#F4){ref-type="fig"}), suggesting that the lower body weights of KPP mice were not due to a failure to grow. KPP mice also exhibited decreased TA, QUAD, and GAST muscle masses ([Figure 4C](#F4){ref-type="fig"}). In the GAST, this decrease in muscle weight was primarily due to decreased cross-sectional area (CSA) of type IIB or IIX muscle fibers ([Figure 4D](#F4){ref-type="fig"}). KPP muscle also showed a trend toward reduced type IIA fiber size (p = 0.06), whereas type I fibers were spared, which is consistent with other mouse models of cancer cachexia ([@R1]; [@R53]). Functionally, muscles from KPP mice exhibited a decrease in total muscle force production at higher stimulation frequencies, but specific force was not altered ([Figure 4E](#F4){ref-type="fig"}), suggesting that the sarcomere structure was intact. Consistent with this phenotype, the content of sarcomeric proteins actin and myosin per mass of muscle was unchanged in KPP mice ([Figure S4B](#SD1){ref-type="supplementary-material"}), which is unlike what we and others have reported in xenograft cachexia models ([@R1]; [@R11]) but in line with reports suggesting that sarcomeric protein content and specific force are maintained in muscles from cachectic cancer patients ([@R65]; [@R69]). Further, night cage activity was decreased, indicating that KPP mice exhibit reduced whole-body function ([Figure 4F](#F4){ref-type="fig"}).

In addition to reduced muscle mass and function, endpoint KPP mice had enlarged spleens ([Figure S4C](#SD1){ref-type="supplementary-material"}), which is a feature of both PDA and cachexia ([@R13]; [@R43]; [@R59]). Furthermore, KPP mice had significantly lower heart masses ([Figure 4G](#F4){ref-type="fig"}), which is also associated with many models of cancer cachexia ([@R13]; [@R43]; [@R59]). KPP mice also had pronouncedly lower white and brown adipose tissue masses ([Figure 4H](#F4){ref-type="fig"}). Consistent with depleted adipose tissue stores, KPP mice displayed an increased resting respiratory exchange ratio (RER), indicative of greater utilization of carbohydrate fuel stores ([Figure 4I](#F4){ref-type="fig"}). Finally, KPP mice consumed less oxygen during dark hours ([Figure 4J](#F4){ref-type="fig"}), which may suggest that carbohydrate utilization is increased or may simply reflect differences in activity ([Figure 4F](#F4){ref-type="fig"}).

To ensure that these cachectic phenotypes were not limited to young mice, where tumor induction was initiated between 3 and 4 weeks of age, we attempted to mimic human PDA in older adults by injecting tamoxifen in 1-year-old KPP mice. Importantly, uninjected KPP mice showed no apparent pancreas pathology, confirming tight regulation of the *Ptf1a^ER-Cre^* allele ([Figure S4D](#SD1){ref-type="supplementary-material"}). In contrast, 1-year-old KPP mice developed PDA with a median post-tumor initiation survival of 158 days ([Figures S4D](#SD1){ref-type="supplementary-material"}--[S4F](#SD1){ref-type="supplementary-material"}) and exhibited weight loss with associated lower masses of skeletal, cardiac, and adipose tissues ([Figures S4G](#SD1){ref-type="supplementary-material"}--[S4J](#SD1){ref-type="supplementary-material"}). Thus, induced cachexia occurs in adult KPP mice.

KPP Mice Undergo Progressive Wasting {#S7}
------------------------------------

Although patients can exhibit cachexia throughout the course of their disease, the incidence of cachexia tends to increase as the disease progresses ([@R19]). To determine whether KPP mice exhibited progressive wasting, we induced tumorigenesis at 24-28 days of age and then euthanized cohorts of mice at 60, 75, and 90 days of age during disease progression, as evidenced by tumor burden ([Figure S5A](#SD1){ref-type="supplementary-material"}). The extent to which the pancreatic parenchyma of KPP mice was replaced by proliferating ductal profiles and accompanying stromal fibrosis increased remarkably with age ([Figure 5A](#F5){ref-type="fig"}). Acinar-to-ductal metaplasia, pancreatic intraepithelial neoplasia (mPanIN), and cystic papillary neoplasms, all of which constitute non-invasive lesions, and occasional focally invasive (early carcinoma) lesions were predominant at 60 and 75 days. Notably, large areas of the exocrine and endocrine pancreas remained unaffected. In contrast, significantly larger portions of the pancreatic parenchyma were replaced by both non-invasive and invasive (advanced carcinoma) lesions at later time points, with severe parenchymal atrophy at 90 days and virtually no remaining histologically normal pancreas by the endpoint.

Although tibia length was not different between control and KPP mice across all time points ([Figure S5B](#SD1){ref-type="supplementary-material"}), KPP mice exhibited a progressive decline in body weight compared with their littermate controls ([Figure 5B](#F5){ref-type="fig"}). Significantly, this decrease in weight matched a progressive decline in skeletal muscle (TA, QUAD, and GAST; [Figure 5C](#F5){ref-type="fig"}), heart ([Figure 5D](#F5){ref-type="fig"}), and adipose mass relative to controls ([Figure 5E](#F5){ref-type="fig"}). In both male and female KPP mice, the decline in both absolute skeletal muscle began between days 75 and 90 ([Figure S5C](#SD1){ref-type="supplementary-material"}), showing that KPP mice exhibit progressive PDA-induced tissue loss, reflective of the human disease. Although KPP mice clearly lose existing adipose tissue, 60-day KPP mice tend to have less adipose tissue than their controls, suggesting that KPP mice may not put on adipose tissue as effectively as control mice during development ([Figure S5D](#SD1){ref-type="supplementary-material"}).

Cachectic Muscle from KPP Mice and PDA Patients Exhibits a Similar Gene Ontology {#S8}
--------------------------------------------------------------------------------

Finally, we compared transcriptional profiles between KPP mice and PDA patients with cachexia ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). In sharp contrast to our findings with the C-26 and LLC xenograft models, only 172 DEGs were identified in KPP mice using an FDR of \< 0.05. However, the five most significant biological process categories identified by gene ontology were related to the extracellular matrix, reminiscent of the cellular component gene ontology of cachectic PDA patients ([Figure S6A](#SD1){ref-type="supplementary-material"}). Furthermore, KPP mice exhibited smaller increases in the expression of E3 ubiquitin ligase and autophagy genes compared with the common xenograft models ([Figures 6C](#F6){ref-type="fig"}--[6F](#F6){ref-type="fig"}), and these modest increases only occurred during end-stage cachexia ([Figure S6B](#SD1){ref-type="supplementary-material"}). Together, these results imply that the cachexia phenotype of KPP mice may more closely resemble that of PDA patients.

DISCUSSION {#S9}
==========

Because mechanistic studies of cancer cachexia are difficult to complete in human patients, our current knowledge of mechanisms of cancer-induced wasting derives mainly from animal models of the disease. However, our work presented here suggests that, in many ways, two of the most commonly used xenograft mouse models of cachexia do not reflect gene expression changes seen in muscle of cachectic PDA patients. This is perhaps not surprising because both the C-26 and LLC models result in aggressive tumors and induce rapid wasting over an approximately 1- to 2-week period ([@R1], [@R2]; [@R26]; [@R59], [@R60]; [@R74]). In addition, the loss of skeletal muscle and adipose mass in these models is generally dependent on inflammatory factors whose concentration in the circulation far exceeds levels recorded in cachectic patients ([@R36], [@R37], [@R38]; [@R41]; [@R58]; [@R61]).

In an effort to better model the cachexia experienced by patients, a number of laboratories have recently published new mouse models of cancer cachexia, often utilizing more relevant cachexia-inducing cancers, with PDA being the most common. The three main approaches of these models have been (1) intraperitoneal injections of PDA cells, which localize to the pancreas; (2) orthotopic models of PDA in which cancer cells are injected directly into the pancreas; and (3) patient-derived xenograft (PDX) models in which a portion of a resected human pancreatic tumor is surgically attached to a mouse pancreas ([@R18]; [@R23]; [@R24]; [@R43]). Although these models have the advantage of establishing tumors within the pancreas, some are limited by their narrow window of wasting, similar to the C-26 and LLC models ([@R24]; [@R43]; [@R72]). Additionally, it is possible that the post-surgical inflammatory environment created by orthotopic injections and surgical tumor implantation contributes to the appearance of wasting rather than deriving from *bona fide,* tumor-induced tissue loss. Finally, use of human tumors or tumor cells necessitates the use of immunocompromised mice, which themselves may fall short in reconstituting the immune profile of cachexia. Thus, although these models may be an improvement over the C-26 or LLC models, they still face challenges in replicating human cancer cachexia.

Although a growing number of reports describe KPC mice as a model of cancer cachexia, in our view, this model also has significant limitations. Although human PDA is estimated to develop over the course of at least a decade ([@R71]), no evidence suggests that mutant Kras is active prior to birth, as in the KPC mouse ([@R25]). Because neonatal skeletal muscle quadruples in size during the first 3 weeks of life ([@R70]), this raises the suspicion that prenatal activation of an oncogene might affect the development of skeletal muscle. This notion is supported by our findings that KPC mice tend to be smaller than their littermate controls regardless of pancreas pathology. An additional consideration with the use of KPC mice as a cachexia model is the propensity of these mice to develop other tumors outside of the pancreas ([@R21]; [@R34]), which might influence how cachexia is interpreted. Admittedly, it may be possible to reduce the incidence of non-pancreas tumors by backcrossing mice into a pure strain, but this remains to be tested. Finally, we speculate that performing pre-clinical cachexia studies would be challenging in the KPC model because the slope of the survival curve of these mice is gradual ([@R27]; [@R56]), meaning large cohorts would likely be required to achieve sufficient power to assess the effectiveness of an anti-cachexia compound.

For our purposes, we sought to use a GEMM of PDA that could overcome some of the shortcomings of the current models. Our findings show that the KPP mouse is suitable as a model of cancer cachexia for several reasons. The inducible nature of the Cre re-combinase utilized in the KPP mouse allows PDA and its associated cachexia to be induced after the rapid neonatal growth of mice has concluded. This allowed us to better model the actual loss of muscle and adipose tissue in patients with PDA, as opposed to potentially slowing development and giving the appearance of cachexia. We also showed that the inducible Cre is amenable to inducing tumor developments older mice, which allows manipulation of experimental conditions associated with PDA in older adults. Moreover, the slope of the survival curve of KPP mice is steeper than that of KPC mice ([Figure S6C](#SD1){ref-type="supplementary-material"}; [@R27]; [@R56]), improving the feasibility of testing potential anti-cachexia compounds.

Although tumor-induced muscle wasting in KPP mice appears to more closely model the cachexia seen in PDA patients, this model is not without limitations. Because KPP mice lose normal pancreatic parenchyma, we cannot exclude the possibility, as reported recently ([@R17]), that pancreatic exocrine insufficiency contributes to tumor-induced wasting in this model. Further, it is possible that features of KPP mice are selective to PDA and, thus, less useful to study other tumor types that also promote cachexia. Despite these limitations, we view the KPP mouse as an improvement over existing animal models of cachexia and anticipate that KPP mice will prove to be a useful tool in improving our understanding of the mechanisms driving tissue wasting and in translating that understanding into new anti-cachexia therapies.

STAR★METHODS {#S10}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S11}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Denis Guttridge (<guttridg@musc.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

### Animals {#S13}

All animal experiments were approved by the Ohio State University Institutional Animal Care and Use Committee under protocol 2010A00000177 or the Medical University of South Carolina Institutional Animal Care and Use Committee under protocol 2018-00328. All animals were housed with littermates and given *ad libitum* access to standard chow and water. C-26 and LLC mice were allocated to tumor-bearing and control groups randomly, genetic models were allocated by genotype.

### C-26 Mice {#S14}

Experiments using the colon-26 (C-26) model were conducted as previously described ([@R26]; [@R59]; [@R62]). Male CD2F1 mice from Charles River Laboratories were injected subcutaneously in the right flank with 1×10^6^ C-26 cells under anesthesia. Control mice received an injection the same volume of phosphate buffered saline. Mice were euthanized by CO~2~ asphyxiation 21 days after injection, at which time tumor-bearing mice had reached IACUC euthanasia criteria of tumor volume or greater than 20% body weight loss.

### LLC Mice {#S15}

Experiments using the Lewis Lung Carcinoma (LLC) model were conducted as previously described ([@R26]; [@R40]; [@R60]). Male C57BL/6J mice from Jackson Laboratories were injected intramuscularly in the right gluteus muscle with 5×10^5^ LLC cells under anesthesia. Control mice received an injection the same volume of phosphate buffered saline. Mice were euthanized by CO~2~ asphyxiation 21 days after injection, at which time tumor-bearing mice had reached IACUC euthanasia criteria of tumor volume or \> 20% weight loss.

### KPC Mice {#S16}

KPC mice (*Kras*^+/*LSL-G12D*^, *Trp53*^+/*R270H*^, *Pdx1*^+/*Cre*^) were provided by the Target Validation Shared Resource of The Ohio State Comprehensive Cancer Center. Mice were maintained on a mixed background ([@R56]). Mice were euthanized by CO~2~ asphyxiation upon reaching IACUC-approved endpoint criteria, which included ascites, weight loss, lethargy, and severe skin papillomas. Both male and female KPC mice were utilized, with same-sex littermates were used as controls.

### KPP Mice {#S17}

Alleles used to generate KPP mice were obtained from Jackson Laboratory on a C57BL/6J background. The initial cohort of KPP mice was generated by breeding *Kras*^*LSL-G12D*/+^, *Pten*^+/*f*^ mice to *Ptf1a*^*ER-Cre*/+^, *Pten*^+/*f*^ mice. Subsequent mice, including all mice euthanized prior to reaching endpoint criteria, were generated by breeding *Kras*^*LSL-G12D*/+^, *Pten*^*f/f*^ mice to *Ptf1a*^*ER-Cre*/+^, *Pten*^*f/f*^ mice. Both male and female KPP mice were utilized, with same-sex littermates were used as controls. Genotypes of control mice appear in [Tables S4](#SD1){ref-type="supplementary-material"}, [S5](#SD1){ref-type="supplementary-material"}, and [S6](#SD1){ref-type="supplementary-material"}.

KPP mice and littermate controls were treated with tamoxifen by five consecutive daily intraperitoneal injections. Mice treated between 24-28 days of age received 1 mg tamoxifen/10 g of body weight, while year-old mice received 2 mg tamoxifen/dose.

Endpoint KPP mice euthanized upon reaching IACUC endpoint criteria, which included ascites, weight loss, lethargy, and a body condition score less than 1.5 ([@R66]). Mice were euthanized at a surgical plane of isoflurane by cardiac puncture followed by cervical dislocation. Final body weights were collected after the draining of ascites fluid. Absence of pancreas pathology was confirmed in all mice utilized as controls by a veterinary pathologist.

Human Subjects {#S18}
--------------

Patients undergoing attempted pancreatic resections at The Ohio State University Wexner Medical Center were asked to participate in a tissue banking protocol under which rectus abdominus muscle biopsies taken during surgery were deposited into a tissue bank run by The Ohio State University Comprehensive Cancer Center Pancreatic Cancer Program. Control muscle tissue was obtained from consenting volunteers without malignancy who were undergoing laparotomy for elective indications (e.g., hernia repair, ostomy reversal). All experiments were approved by The Ohio State University Cancer Institutional Review Board and all patients provided informed consent.

Patients with greater than 5% loss of their pre-illness weight were classified as cachectic ([@R20]). When possible, self-reported weight loss was supported by a patient's existing medical record. All tissue samples used in this analysis were from patients who had not received chemotherapy or radiation prior to surgery for this incidence of cancer. A previous history of a cancer was not an exclusionary criterion. Clinical characteristics of the patients from which muscle was used for RNA-Seq are included in [Table S2](#SD1){ref-type="supplementary-material"}, with characteristics of patients used for RT-PCR in [Table S3](#SD1){ref-type="supplementary-material"}. RNA-Seq was conducted on muscle from male subjects, while RT-PCR was performed on a roughly even mix of male and female subjects.

METHOD DETAILS {#S19}
--------------

### RNA-Seq and Gene Ontology {#S20}

RNA was isolated from snap-frozen tibialis anterior (mouse) or rectus abdominus (human) muscle using Trizol reagent (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. RNA quality was assessed using an Agilent Bioanalyzer RNA 6000 Nano chip and RIN numbers for all samples were greater than 7. rRNA was removed from purified total RNA using Ribo-Zero Gold rRNA Removal kit (Illumina; MRZG12324). 200 ng of rRNA-depleted RNA was used for the construction of the library using the SureSelect Strand Specific RNA library prep kit (Agilent; G9691A) according to the manufacturer's instruction, except for omitting the purification step before fragmentation. Barcoded libraries were pooled and sequenced using an Illumina HiSeq4000.

For muscle samples from mice, raw reads were aligned to *Mus musculus* GRCm38 from ensembl with tophat2v2.1.0 ([@R32]) which ran with gene model annotations provided by GRCm38 v83. Sequence for samples from multiple lanes were combined. Alignment QC was generated with RSeQCv2.6.4 ([@R68]) and picardv2.4.1 (<http://broadinstitute.github.io/picard>). Fragment counts were generated with featureCounts v1.4.5 ([@R39]) from the subread package for genes described by ensembl GRCm38 v83. For reads with multiple alignments, the primary alignment was counted by featureCounts. Strand-specific read counting was performed based on sequence that is reversely stranded. Differential expression was performed with limma ([@R52]) for genes with CPM \> 2 in 4 or more samples.

For muscle samples from patients, raw reads for human samples were aligned to *Homo sapiens* GRCh38 with HISAT2 v2.0.5 ([@R33]). Alignment QC was generated with RSeQCv2.6.4 ([@R68]) and picardv2.4.1 (<http://broadinstitute.github.io/> picard). Fragment counts were generated with featureCounts v1.4.5 ([@R39]) from the subread package for genes described by ensembl GRCh38 v86. For reads with multiple alignments, the primary alignment was counted by featureCounts. Strand-specific read counting was performed based on sequence that is reversely stranded. Differential expression was performed with limma ([@R52]) for genes with CPM \> 2 in more than half the samples. For human samples, gene downregulation confirmed by real-time RT-PCR for 9 samples with RNA available. For both human and mouse samples, gene ontology was performed using the ToppFun application of the ToppGene Suite ([@R14]). Heatmaps were produced with Morpheus from the Broad Institute (<https://software.broadinstitute.org/morpheus>).

### Real-Time RT-PCR {#S21}

Messenger RNA was isolated from snap-frozen quadriceps (mouse) or rectus abdominus (human) muscle using Trizol reagent (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. M-MLV Reverse Transcriptase (Life Technologies) was used to reverse-transcribe total RNA to cDNA according to the manufacturer's instructions. Real-time PCR was performed on an Applied Biosystems StepOnePlus instrument using SYBR Green mix (Bio-Rad, Hercules, CA). GAPDH was used as the housekeeping gene. Primer sequences appear in [Table S7](#SD1){ref-type="supplementary-material"}.

### Pancreas Histopathology {#S22}

Formalin-fixed, paraffin-embedded, hematoxylin-and-eosin-stained pancreata of KPC and KPP mice were assessed by a veterinary pathologist employing recommended nomenclature for pancreatic exocrine neoplasia ([@R28]). To better characterize the lesions, pancreas sections from endpoint KPP mice were stained for Alcian blue to detect mucin and glycoproteins, Ki67 (1:200), α-smooth muscle actin (α-SMA, 1:5000), and cytokeratin 19 (CK19, 1:500). The sections were imaged using a Vectra Multispectral Imaging System (Perkin-Elmer).

### CLAMS {#S23}

Endpoint KPP mice (n = 5) were single-housed in a Comprehensive Lab Animal Monitoring System (CLAMS) unit (Columbus Instruments, Columbus, OH) for 24 hours prior to euthanasia. Environmental temperature was held constant at 25 °C. Mice were placed in the unit at 10 AM, and daytime data were collected from 12 PM until five minutes prior to lights out. Night data were collected from one hour after lights out until 5 minutes prior to lights on.

### Muscle Fiber Size Measurements {#S24}

Muscle fiber cross-sectional area (CSA) of individual fiber types was determined from 10 μM sections of gastrocnemius stained for laminin, myosin heavy chain Type IIA, and myosin heavy chain Type I by a modification of Minnaard ([@R44]). Muscle fiber CSA was determined using a semi-automated ImageJ plug-in designed in the Guttridge lab which outlines the internal laminin border of individual muscle fibers and then assigns fiber types based upon color of the fiber.

### Muscle Function Measurements {#S25}

Extensor digitorum longus (EDL) force production was measured across a force-frequency curve. Force was normalized to CSA as previously described ([@R55]).

### Sarcomeric Protein Analysis {#S26}

Muscle sarcomere components were analyzed as previously described ([@R10]).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S27}
---------------------------------------

Statistical analysis was conducted with GraphPad Prism 7, and the details of these analyses appear in the figure legends with samples per group (n). Unless otherwise noted, data are presented as mean ± the standard error of the mean (SEM). For KPC and KPP mice, comparisons between groups were made by two-tailed paired t tests. For C-26 and LLC mice and comparisons between human subjects, unpaired two-tailed tests were used. Statistical analysis of tissue masses was conducted on absolute values, regardless of the presentation of the data. Statistical significance was defined *a priori* as p \< 0.05.

DATA AND CODE AVAILABILITY {#S28}
--------------------------

Raw RNA-Seq data files are available in the NCBI's GEO: GSE133523 and GSE133524.
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![Comparing Xenograft Models with Cachectic Pancreatic Cancer Patients\
(A) RNA-seq of *tibialis anterior* (TA) muscle from C-26 and LLC tumor-bearing mice (n = 2 males per group).\
(B) RNA-seq of n = 5 male non-cancer patients and 5 male cachectic PDA patients.\
(C--F) Gene expression of (C) Atrogin-1, (D) MuRF1, (E) Atg5, and (F) Bnip3 (n = 8 males for C-26; n = 6 males for LLC; n = 11 controls, 17 cachectic patients, approximately equal male and female).\
Patient characteristics for RNA-seq can be found in [Table S2](#SD1){ref-type="supplementary-material"}, and patient characteristics for RT-PCR can be found in [Table S3](#SD1){ref-type="supplementary-material"}. Bars represent mean ± SEM. Closed circles represent individual data points. \*p \< 0.05 in a t test.\
See [Figure S1](#SD1){ref-type="supplementary-material"} for additional information.](nihms-1536799-f0001){#F1}

![The KPC Mouse as a Model of Cancer Cachexia\
(A--C) KPC mice that have reached endpoint criteria have lower body weights (A; n = 11), muscle weights (B; n = 11), and gonadal white adipose tissue masses (C; n = 5) than littermate control mice.\
(D--F) However, when pancreatic histopathology is considered (D), mice with mPanIN lesions (n = 4), early PDA (n = 4), and advanced PDA (n = 3) all tend to have lower body weights (E) and muscle weights (F).\
Bars represent mean ± SEM. Closed circles represent individual data points. \*p \< 0.05 in a paired t test on absolute weights. Scale bars, 50 μm.\
See [Figure S2](#SD1){ref-type="supplementary-material"} for additional information.](nihms-1536799-f0002){#F2}

![Generation of the KPP Mouse and Endpoint Analysis\
(A) The alleles of the KPP mouse.\
(B) Naive *Ptfa1^ER-Cre/^+;Rosa26Tomato^+/−^* mice express background fluorescence in pancreas sections, whereas pancreata of tamoxifen-treated *Ptfa1^ER-Cre/+^;Rosa26Tomato^+/−^* mice exhibit a high fluorescence signal.\
(C) KPP mice induced with tamoxifen between 24 and 28 days of age had an average survival of 107 days of age (n = 12). Ticks on the control line indicate points when a control mouse was euthanized for comparison with a littermate KPP mouse. Control genotypes include *Kras^+/+^, Ptf1a^+/ER-Cre^, Pten^f/f^* (n = 6), *Kras^+/+^, Ptf1a^+/ER-Cre^, Pten^+/+^* (n = 1), *Kras^+/+^, Ptf1a^+/ER-Cre^, Pten^+/+^* (n = 1), *Kras^+/G12D^, Ptf1a^+/+^, Pten^f/f^* (n = 1), and *Kras^+/+^, Ptf1a^+/+^, Pten^+/f^* (n = 3). Control genotypes are presented with their paired KPP mouse in [Table S4](#SD1){ref-type="supplementary-material"}.\
(D) Endpoint KPP mice demonstrate moderately well-differentiated to well-differentiated PDA as evidenced by H&E, Alcian blue, CK19, Ki67, and α-smooth muscle actin (α-SMA) staining. Scale bar, 50 μm.\
See [Figure S3](#SD1){ref-type="supplementary-material"} for additional information.](nihms-1536799-f0003){#F3}

![The KPP Mouse Develops Cachexia\
(A and B) KPP mice are smaller than their littermate controls when reaching endpoint criteria (A) but have similar tibia lengths (B).\
(C) KPP mice exhibit reduced TA, quadriceps (QUAD), and gastrocnemius (GAST) muscle masses.\
(D) Muscle wasting in KPP GAST is associated with lower type IIB or IIX fiber cross-sectional area, whereas type IIA fibers tended to be smaller (p = 0.06).\
(E) Absolute *ex vivo* extensor digitorum longus (EDL) muscle force was significantly reduced at higher stimulation frequencies, but specific force was not altered.\
(F) Endpoint KPP mice demonstrate decreased night (awake) activity counts, indicative of depressed whole-body function.\
(G and H) KPP mice demonstrate decreased heart weight (G) and decreased masses of gonadal white and subscapular brown adipose (H).\
(I) Consistent with decreased adipose tissue stores, KPP mice exhibit an increased daytime respiratory exchange ratio (RER).\
(J) KPP mice exhibited decreased night oxygen consumption (VO~2~).\
Bars represent mean ± SEM. Closed circles represent individual data points. \*p \< 0.05 in a paired t test. n = 12 per group; for cross-sectional area and metabolic data, n = 5 per group, and for muscle function data, n = 3 per group. Even when expressed as percent controls, statistical tests were conducted on absolute weights.\
See [Figure S4](#SD1){ref-type="supplementary-material"} for additional information.](nihms-1536799-f0004){#F4}

![KPP Mice Exhibit Progressive Cachexia Associated with Advancing Pancreas Pathology\
(A) Pancreatic disease in KPP mice progresses across their lifespan.\
(B--E) Additionally, compared with their littermate controls, KPP mice progressively lose bodyweight (B) , skeletal muscle (C), heart mass (D), and white and brown adipose tissue (E).\
Bars represent mean ± SEM. Closed circles represent individual data points. "Endpoint" KPP mice have reached Institutional Animal Care and Use Committee (IACUC) euthanasia criteria and are the same mice as shown in [Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"} (n = 12). n = 5--6 mice per group for the 60-, 75-, and 90-day time points. Genotypes for each control mouse can be found in [Table S6](#SD1){ref-type="supplementary-material"}. \*p \< 0.05 in a paired t test on absolute weights. Scale bar, 50 μm.\
See [Figure S5](#SD1){ref-type="supplementary-material"} for additional information.](nihms-1536799-f0005){#F5}

![The Gene Ontology of KPP Mice Resembles that of Cachectic PDA Patients\
(A) RNA-seq of TA muscle from KPP mice (n = 2 males per group).\
(B) RNA-seq of n = 5 male non-cancer patients and 5 male cachectic PDA patients.\
(C--F) Gene expression of (C) Atrogin-1, (D) MuRF1, (E) Atg5, and (F) Bnip3 (n = 8 males for C-26; n = 6 males for LLC, n = 3 males and 3 females for KPP; n = 11 controls, 17 cachectic patients, approximately equal male and female).\
Patient characteristics for RNA-seq can be found in [Table S2](#SD1){ref-type="supplementary-material"}, and patient characteristics for RT-PCR can be found in [Table S3](#SD1){ref-type="supplementary-material"}. Bars represent mean ± SEM. Closed circles represent individual data points. \*p \< 0.05 in a t test.\
See [Figure S6](#SD1){ref-type="supplementary-material"} for additional information.](nihms-1536799-f0006){#F6}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                           SOURCE                                                                         IDENTIFIER
  ----------------------------------------------------------------------------- ------------------------------------------------------------------------------ -----------------------------
  Antibodies                                                                                                                                                   
  Ki67                                                                          Abcam                                                                          ab16667; RRID: AB_302459
  α-smooth muscle actin (α-SMA)                                                 Abcam                                                                          ab5694; RRID: AB_2223021
  cytokeratin 19 (CK19)                                                         Iowa Development Studies Hybridoma Bank                                        TROMA-III; RRID: AB_2133570
  laminin                                                                       ThermoScientific                                                               MA1-06100; RRID: AB_559896
  myosin heavy chain Type I                                                     Iowa Development Studies Hybridoma Bank                                        A4.840; RRID: AB_528384
  myosin heavy chain Type IIA                                                   Iowa Development Studies Hybridoma Bank                                        sc-71; RRID: AB_2147165
  Biological Samples                                                                                                                                           
  rectus abdominus muscle biopsies                                              Pancreatic cancer patients and control patients undergoing abdominal surgery   N/A
  Deposited Data                                                                                                                                               
  Raw RNA-Seq files (human)                                                     This paper                                                                     GEO: GSE133523
  Raw RNA-Seq files (mouse)                                                     This paper                                                                     GEO: GSE133524
  Experimental Models: Cell Lines                                                                                                                              
  Colon-26 (C-26)                                                               National Cancer Institute                                                      N/A
  Lewis Lung Carcinoma (LLC)                                                    National Cancer Institute                                                      N/A
  Experimental Models: Organisms/Strains                                                                                                                       
  *Kras^LSL-G12D^* (KPP)                                                        The Jackson Laboratory                                                         \#008179
  *Pten^f/f^*                                                                   The Jackson Laboratory                                                         \#006440
  *Ptf1a^ER-Cre^*                                                               The Jackson Laboratory                                                         \#019378
  *Rosa26-tdTomato*                                                             The Jackson Laboratory                                                         \#007914
  *Kras^LSL-G12D^* (KPC)                                                        NCI Frederick Mouse Repository                                                 01XJ6
  *Pdx1^Cre^*                                                                   NCI Frederick Mouse Repository                                                 01XL5
  *Trp53*+/^*R270H*^                                                            NCI Frederick Mouse Repository                                                 01XM3
  Oligonucleotides                                                                                                                                             
  Primers for RT-PCR, see [Table S7](#SD1){ref-type="supplementary-material"}   This paper, [@R59]                                                             N/A
  Software and Algorithms                                                                                                                                      
  tophat2                                                                       [@R32]                                                                         v2.1.0
  HISAT2                                                                        [@R33]                                                                         v2.0.5
  featureCounts                                                                 [@R39]                                                                         v1.4.5
  RSeQC                                                                         [@R68]                                                                         v2.6.4

###### Highlights

-   Development of a mouse model of pancreatic adenocarcinoma (PDA)-induced cachexia

-   Model develops progressive wasting associated with advancing pancreas pathology

-   Induction of cachexia in adult KPP mice models tissue loss in PDA cancer patients

-   Gene ontology of cachectic muscles from KPP mice resembles that of PDA patients
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